MDL 28170: Selective Calpain and Cathepsin B Inhibitor for Neuroprotection and Apoptosis Research

Executive Summary: MDL 28170 is a potent, membrane-permeable inhibitor of calpain and cathepsin B, exhibiting Ki values of 10 nM and 25 nM, respectively, with established selectivity over serine proteases (APExBIO). It rapidly crosses the blood-brain barrier, enabling systemic administration for central nervous system research (Zhang et al., 2025). Pharmacological inhibition of calpain by MDL 28170 restores hippocampal BDNF/TrkB signaling and synaptic integrity after perinatal injury. The compound is validated in both neurodevelopmental and cardiac ischemia models, and it exhibits antiparasitic activity against Trypanosoma cruzi trypomastigotes (APExBIO). MDL 28170 is insoluble in water but highly soluble in DMSO and ethanol, supplied as a solid and recommended for prompt use of solutions.

Biological Rationale

Calpains and cathepsin B are cysteine proteases implicated in cellular damage during pathological conditions such as ischemia-reperfusion injury, neurodegenerative disease, and infection (Zhang et al., 2025). Excessive calpain activation disrupts neuronal integrity by degrading cytoskeletal proteins, impairing dendritic spine morphology, and inhibiting crucial neurotrophic signaling pathways like BDNF/TrkB (Zhang et al., 2025). Cathepsin B is involved in lysosomal-mediated apoptosis and may exacerbate tissue injury during oxidative stress. Inhibition of these proteases is a validated strategy for protecting neuronal and myocardial tissue during acute injury and chronic degenerative processes. MDL 28170, supplied by APExBIO, is designed for selective inhibition of these proteases without affecting trypsin-like serine proteases, ensuring specificity in experimental systems (APExBIO).

Mechanism of Action of MDL 28170 (Calpain and Cathepsin B Inhibitor, Selective)

MDL 28170 is a reversible, competitive inhibitor that binds to the catalytic domain of calpains and cathepsin B, blocking substrate access and enzymatic activity (APExBIO). The compound exhibits nanomolar affinity for calpain (Ki = 10 nM) and cathepsin B (Ki = 25 nM) in cell-free systems at 25°C, pH 7.4. Its membrane-permeable properties facilitate rapid intracellular accumulation and effective enzyme inhibition in both cytoplasmic and lysosomal compartments. In the brain, MDL 28170 reduces calpain-mediated proteolysis of cytoskeletal and synaptic proteins, thereby preserving neuronal structure and function. In cardiac tissue, inhibition of calpain activity by MDL 28170 protects sarcomere integrity and reduces myocardial injury (APExBIO; Related Article). The compound does not inhibit trypsin-like serine proteases at concentrations up to 100 μM, supporting its selectivity profile.

Evidence & Benchmarks

• Systemic administration of MDL 28170 (10 mg/kg, postnatal day 1–7, intraperitoneal) restored hippocampal BDNF/TrkB protein levels and improved spatial learning in offspring after maternal surgery-induced neurodevelopmental injury (Zhang et al., 2025, Table 2).
• MDL 28170 reduced calpain activity in brain tissue lysates by >80% at 1 μM (in vitro assay, 37°C, pH 7.4) (Zhang et al., 2025, Figure 3C).
• In cardiac ischemia-reperfusion models, MDL 28170 preserved sarcomere structure and improved left ventricular ejection fraction by 18% compared to vehicle controls (APExBIO).
• MDL 28170 decreased viability of Trypanosoma cruzi trypomastigotes in vitro with an EC₅₀ of 0.6 μM (24 h, 37°C) (APExBIO).
• No inhibition of trypsin-like serine proteases was observed at concentrations up to 100 μM (enzyme panel, 25°C, pH 8.0) (APExBIO).

For extended mechanistic and translational insights, see this article, which integrates MDL 28170 in ischemia-reperfusion models; this current dossier further details its neurodevelopmental application and quantitative inhibition profiles.

Applications, Limits & Misconceptions

MDL 28170 is widely used in:

• Apoptosis assays where calpain- or cathepsin B-mediated proteolysis is implicated.
• Neuroprotection research, especially in models of ischemia, oxidative stress, and neurodegeneration (Related Article; this article provides updated compound handling and specificity data).
• Cardiac ischemia-reperfusion injury models, for preservation of myocardial ultrastructure.
• Parasitology, including in vitro assays targeting Trypanosoma cruzi viability.
• Workflow integration for caspase pathway dissection and advanced disease modeling.

Despite its broad utility, MDL 28170 is not effective against serine proteases or metalloproteases and is not recommended for use in water-based solvents due to insolubility. For a discussion of its translational relevance and advanced cysteine protease inhibition, see this article; our current coverage highlights new in vivo validation and practical handling guidance.

Common Pitfalls or Misconceptions

• MDL 28170 does not inhibit trypsin-like serine proteases or metalloproteases at relevant concentrations (APExBIO).
• It is insoluble in water; use DMSO or ethanol for solution preparation (≥16.75 mg/mL in DMSO, ≥25.05 mg/mL in ethanol with ultrasound).
• Long-term storage of solutions is not recommended; use freshly prepared aliquots, storing the solid at -20°C.
• Not validated for oral administration or chronic dosing in clinical settings.
• Specificity must be confirmed in complex biological matrices to rule out off-target effects.

Workflow Integration & Parameters

MDL 28170 is supplied as a solid (SKU A4412) and should be stored at -20°C (APExBIO). For in vitro use, dissolve to the desired concentration in DMSO or ethanol. Solutions should be prepared fresh and used promptly. For in vivo applications, established protocols employ intraperitoneal administration at 10 mg/kg in rodent models, with rapid blood-brain barrier penetration confirmed (Zhang et al., 2025). Calpain and cathepsin B inhibition should be monitored by activity assays or immunoblotting for proteolytic substrates. MDL 28170 is compatible with neurodevelopmental, cardiac, apoptosis, and parasitology research workflows. For scenario-based guidance, see this Q&A article; the present dossier clarifies compound stability and storage details.

Conclusion & Outlook

MDL 28170 (Calpain and Cathepsin B Inhibitor, Selective) provides a unique combination of selectivity, potency, and cell-permeability for advanced studies of cysteine protease function in neuroprotection and apoptosis. Its validated efficacy in both preclinical neurodevelopmental and cardiac models, as well as in parasitology, underscores its value for translational research. Proper handling, specificity confirmation, and workflow integration are critical for reliable results. For ordering and further technical information, visit the APExBIO MDL 28170 product page. For additional context on selectivity and disease modeling, see this article; this current dossier provides updated mechanistic and application benchmarks.